A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Phase 3
1,046
about 7.2 years
18+
36 sites in AZ, CA, CO +18
About this study
Researchers are testing if a new treatment combination with zilovertamab vedotin plus rituximab can help people live longer without the cancer growing or spreading than standard treatment alone. The trial will last for 2618 days and involve approximately 1046 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Rituximab
- 2.Receive Rituximab Biosimilar
- 3.Receive Zilovertamab vedotin
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), methylprednisolone, prednisolone, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), biologic (immunotherapy) (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, injection (Injection), oral (Disintegrating Oral Tablet), oral
Primary: Progression-free survival (PFS)
Secondary: Change From Baseline in HRQoL on FACT-Lym Physical Wellbeing (PWB) Score, Change From Baseline in HRQoL on FACT-Lym Total Score, Change From Baseline in HRQoL on Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) Neurotoxicity Subscale Score, Change From Baseline in Health-Related Quality Of Life (HRQoL) on Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Trial Outcome Index (TOI) Score, Complete Response at End of Treatment (CR at EOT), Event-free Survival (EFS), Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience an Adverse Event (AE)
Oncology